Format

Send to

Choose Destination
Kidney Int. 2016 Sep;90(3):638-47. doi: 10.1016/j.kint.2016.04.008. Epub 2016 Jun 7.

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.

Author information

1
Renal Division, Massachusetts General Hospital, Boston, Massachusetts, USA.
2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.
3
Department of Pathology, Oregon Health and Science University, Portland, Oregon, USA.
4
Division of Nephrology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
5
Memorial Sloan Kettering Cancer Center, New York, New York, USA.
6
Department of Pathology, Mayo Clinic, Rochester, Minnesota, USA.
7
Advanced Kidney Care of Hudson Valley, Poughkeepsie, New York, USA.
8
Department of Pathology, Columbia University Medical Center, New York, New York, USA.
9
Division of Nephrology, Kaiser Permanente, Portland, Oregon, USA.
10
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
11
Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
12
Divison of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. Electronic address: DELEAF@partners.org.

Abstract

Immune checkpoint inhibitors (CPIs), monoclonal antibodies that target inhibitory receptors expressed on T cells, represent an emerging class of immunotherapy used in treating solid organ and hematologic malignancies. We describe the clinical and histologic features of 13 patients with CPI-induced acute kidney injury (AKI) who underwent kidney biopsy. Median time from initiation of a CPI to AKI was 91 (range, 21 to 245) days. Pyuria was present in 8 patients, and the median urine protein to creatinine ratio was 0.48 (range, 0.12 to 0.98) g/g. An extrarenal immune-related adverse event occurred prior to the onset of AKI in 7 patients. Median peak serum creatinine was 4.5 (interquartile range, 3.6-7.3) mg/dl with 4 patients requiring hemodialysis. The prevalent pathologic lesion was acute tubulointerstitial nephritis in 12 patients, with 3 having granulomatous features, and 1 thrombotic microangiopathy. Among the 12 patients with acute tubulointerstitial nephritis, 10 received treatment with glucocorticoids, resulting in complete or partial improvement in renal function in 2 and 7 patients, respectively. However, the 2 patients with acute tubulointerstitial nephritis not given glucocorticoids had no improvement in renal function. Thus, CPI-induced AKI is a new entity that presents with clinical and histologic features similar to other causes of drug-induced acute tubulointerstitial nephritis, though with a longer latency period. Glucocorticoids appear to be a potentially effective treatment strategy. Hence, AKI due to CPIs may be caused by a unique mechanism of action linked to reprogramming of the immune system, leading to loss of tolerance.

KEYWORDS:

acute kidney injury; ipilimumab; nivolumab; pembrolizumab

PMID:
27282937
PMCID:
PMC4983464
DOI:
10.1016/j.kint.2016.04.008
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center